Archive


Category: Bispecific

  • 3rd Cell Engager Summit

    With that in mind, the 3rd Cell Engager Summit (June 30 – July 1) is the only industry-led meeting focused on developing multi-specific cell engaging therapies in solid tumor indications, and accelerating early discovery innovation into the clinic. With over 32 world-class speakers set to share their ground-breaking insights, this is a learning and networking experience you won’t want to […]

  • Roche Highlights its Bispecific Antibody Portfolio Across a Range of Blood Cancers at ASH 2020

    Shots: The company presented the new data of its T-cell engaging bispecific Abs, mosunetuzumab, glofitamab and cevostamab at ASH 2020, demonstrating encouraging activity across multiple types of blood cancer Roche divulges that its mosunetuzumab & glofitamab showed promising responses across multiple types of NHL, including R/R FL & DLBCL, reinforcing from the P-I/Ib GO29781 study […]